title: A novel biological target for the treatment of psoriatic arthritis.
abstract: Evaluation of: Kavanaugh A, Ritchlin C, Rahman P et al.; on behalf of the PSUMMIT-1 and -2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the Phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis. 73(6), 1000-1006 (2014). The IL-23/IL-17 axis plays a major role in the immunopathogenesis of psoriatic arthritis (PsA), inducing the production of proinflammatory cytokines (e.g., IL-1, TNF-α, IL-6 and IL8), osteoclastogenesis and cartilage degradation. This pathway represents a novel target in the treatment of PsA. Ustekinumab is a human monoclonal antibody that prevents the human IL-12/IL-23 p40 subunit from binding to the IL12Rβ1 receptor chain. The current paper sustains that clinical efficacy of ustekinumab is associated with inhibition of radiological progression in active PsA.
authors.affiliation: Dipartimento di Medicina Interna e Specialità Mediche, UOC di Reumatologia, "Sapienza", Università di Roma, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Spadaro
authors.forename: Monica
authors.initials: M
authors.lastname: Montepaone
authors.forename: Ennio
authors.initials: E
authors.lastname: Lubrano
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D005260:Female; D033023:Foot Joints / Q000000981:diagnostic imaging*; D050823:Hand Joints / Q000000981:diagnostic imaging*; D006801:Humans; D053762:Interleukin-12 Subunit p40 / Q000037:antagonists & inhibitors*; D008297:Male; D011859:Radiography
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D053762:Interleukin-12 Subunit p40
keywords: IL-23/IL17 axis; biologic agent; psoriatic arthritis; radiographic progression; ustekinumab